Redeye updates its estimates and fair value range following BICO’s Q3 2025 report showing a return to organic growth in line with our projections. It also showed a slight beat on sales and adjusted EBITDA compared to our estimates, on account of stronger-than-anticipated Lab Automation sales. BICO trades at an EV/S of 0.5x and an EV/EBITDA of 12x on Redeye's 2026e projections.
LÄS MER